The Genomic Allergen Rapid Detection platform: An in vitro sensitization assay
|SPEAKER:||Joshua J. Schmidt, PhD, Business Development Director-Americas, SenzaGen Inc.|
Oct 09, 2019
This webinar will describe development of the Genomic Allergen Rapid Detection (GARD) platform and its applicability for testing both skin and respiratory sensitizing chemicals. The assay is based on a human DC-like cell line and uses state-of-the-art machine learning algorithms to classify unknown test substances based on the readout from genomic biomarker signatures of genes involved in immunologically relevant pathways. Genes in the biomarker signatures were initially selected using a data-driven approach from transcriptome-wide profiling on a microarray platform. Following discovery and selection of genes in the biomarker signatures, measurements were transferred to the NanoString® nCounter® platform (For Research Use Only) to enable higher sample throughput within a resource effective, simple and highly automated protocol with minimal hands-on time.
The presentation will illustrate the robustness and reliability generated by in vitro models based on genomic biomarker signatures. The webinar will also demonstrate the benefits of embracing novel transcriptomic technologies, emerging computational tools and powerful machine learning approaches to arrive at more mechanistically relevant and well-informed in vitro hazard decisions with accuracies superior to current animal models.
FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.